Random
This phase of the cell cycle represents quiescent, non-dividing cells that are largely resistant to chemotherapy.
G0
This class of drugs is S-phase specific and works by mimicking purine or pyrimidine nucleotides.
Antimetabolites
This is the most common dose-limiting toxicity across traditional chemotherapeutic agents.
Myelosuppression and Nausea/Vomiting
This type of therapy is given after primary surgery or radiation to decrease local and systemic recurrence, while its counterpart is given before surgery to reduce tumor volume.
Adjuvant vs neoadjuvant therapy
These drugs stabilize microtubules and prevent their disassembly, leading to mitotic arrest.
Taxanes
This toxic metabolite causes hemorrhagic cystitis in patients receiving cyclophosphamide or ifosfamide.
Acroleine
This hypothesis explains that chemotherapy kills a constant proportion of cancer cells rather than a constant number.
The Fractional Kill (Log-Kill) Hypothesis
This drug inhibits dihydrofolate reductase, preventing formation of tetrahydrofolate required for DNA synthesis.
Methotrexate
This platinum agent causes acute cold-induced paresthesias and laryngospasm shortly after infusion.
Oxaliplatin
This platinum-based chemotherapy combination is commonly used for non-small cell lung cancer.
Carboplatin and paclitaxel
These agents stabilize DNA–topoisomerase complexes, leading to DNA strand breaks and cell death.
Topoisomerase inhibitors
This drug causes redness, pain, and swelling in the hands and feet.
Capecitabine (A Pyrimidine Analogue)
This class of chemotherapeutic agents used in breast cancer causes dose-dependent cardiomyopathy and requires routine cardiac monitoring.
Anthracyclines
Where do alkylating agents covalently bind DNA to disrupt replication and transcription?
The N7 position of guanine
Deficiency in this enzyme leads to severe toxicity with 5-FU and capecitabine.
Dihydropyrimidine dehydrogenase (DPD)